MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-07-2022
AVEO Pharmaceuticals Retained Earnings 2011-2026 | AVEO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -675 M | -621 M | -586 M | -595 M | -587 M | -522 M | -495 M | -480 M | -427 M | -320 M | -206 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -206 M | -675 M | -501 M |
Quarterly Retained Earnings AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -696 M | - | -685 M | -675 M | -667 M | -657 M | -643 M | -621 M | -621 M | -621 M | -621 M | -586 M | -586 M | -586 M | -586 M | -595 M | -595 M | -595 M | -595 M | -587 M | -587 M | -587 M | -587 M | -522 M | -522 M | -522 M | -522 M | -495 M | -495 M | -495 M | -495 M | -480 M | -480 M | -480 M | -480 M | -427 M | -427 M | -427 M | -427 M | -320 M | -320 M | -320 M | -320 M | -206 M | -206 M | -206 M | -206 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -206 M | -696 M | -508 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.63 | -2.16 % | $ 1.08 B |  Canada |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
ADMA Biologics
ADMA
|
-162 M | $ 16.54 | 0.98 % | $ 3.94 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
-3.01 B | $ 19.86 | -1.49 % | $ 2.51 B | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.83 | 4.19 % | $ 4.53 M | China |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
-100 M | $ 76.53 | 0.57 % | $ 1.48 B | USA |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-233 M | $ 3.43 | 5.54 % | $ 4.01 M | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
643 M | $ 35.69 | 1.16 % | $ 3.71 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
474 M | $ 24.69 | 3.22 % | $ 3.02 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-437 M | $ 8.42 | 2.56 % | $ 36.4 M | USA |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 164.08 | 0.02 % | $ 8.16 B | USA |
 |
CorMedix
CRMD
|
-322 M | $ 7.12 | 3.04 % | $ 362 M | USA |
 |
Champions Oncology
CSBR
|
-79.9 M | $ 6.0 | - | $ 82 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-201 M | $ 0.82 | 10.34 % | $ 5.52 M | USA |
 |
BridgeBio Pharma
BBIO
|
-3.82 B | $ 66.54 | 3.11 % | $ 12.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-227 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Denali Therapeutics
DNLI
|
-1.54 B | $ 20.37 | 1.75 % | $ 3.35 B | USA |
 |
Edesa Biotech
EDSA
|
-58.6 M | $ 4.27 | -1.84 % | $ 13.7 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
-186 M | $ 1.75 | -1.13 % | $ 60.8 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | USA |